Navigation Links
Canada-wide study on slow progressors to investigate new treatments for HIV
Date:2/6/2009

This press release is available in French.

Montreal, Febrauary 6, 2009 -- Why do some HIV patients manage to control the progression of their infection naturally over long periods of time? As part of a nation-wide investigation, a team of researchers will examine that question and others as they work to develop new strategies to fight AIDS.

The five-year study will be headed by Dr. Ccile Tremblay, a physician and investigator with the Centre hospitalier de l'Universit de Montral's Research Centre (CRCHUM) and a professor at the Universit de Montral, thanks to nearly $1 million in support from the Canadian Institutes for Health research (CIHR).

In light of a limited success in developing vaccine therapies, it has become clear that the scientific community needs to place greater emphasis on the basic research necessary to address the many unanswered questions that remain about HIV. One of the best approaches to try to develop effective vaccines is the study of HIV-infected individuals who control their infection naturally and do not show disease progression over a long period of time. Called slow progressors (SP), these individuals make up less than 1percent of HIV-infected population. Some of the questions that this study will address include:

  • What constitutes a protective immune response?
  • What are the drivers of HIV diversity?
  • Can we develop broadly neutralizing antibodies?
  • And, ultimately, how can this understanding lead to the development of an effective vaccine?

Conducting a study of this nature requires a sufficiently large pool of slow progessors. Enter Dr. Tremblay, whose team has assembled a unique cohort of slow progessors in Quebec and, thanks to the CIHR funding, she will expand it throughout Canada. This national effort will involve the collaboration of major HIV clinical scientists across the country, including in Toronto, Vancouver and Victoria, as well as international colleagues.

The cohort will enable researchers to gather important information concerning the clinical course of HIV, which may lead to the identification of factors that predict a favourable outcome. The study will enable the collection of samples that will be stored in a specimen bank, which will be made available to various investigators investigating the progression of HIV.

The project aims to determine the natural history of the disease over a five-year period. It will also focus on the impact of viral genetic evolution on the immune system through the collection of clinical, demographic, social and behavioural data that will be analyzed in correlation with virological, immunological and genetic findings.


'/>"/>

Contact: Nathalie Forgue
nathalie.forgue.chum@ssss.gouv.qc.ca
51-489-080-001-4342
University of Montreal
Source:Eurekalert

Related medicine news :

1. New Vivisimo Case Study Details Medical Search
2. Penn study shows how electronic medical records can be used to test drug efficacy
3. Genome Study Points to New Culprit for Schizophrenia
4. New Clinical Study Presented at the Society for Critical Care Medicine Shows Value of Pulse CO-Oximetry(TM) to Identify Acquired Methemoglobinemia
5. New Study Provides Benchmarks for Best Practices for Valuing Internal Consulting Organizations
6. MSU study finds high level of medical mistrust among minority women impacts quality of health care
7. Transition Therapeutics Announces Completion of Patient Enrolment of Phase 2 Study of TT-223 in Type 2 Diabetes Patients
8. New study raises concerns about screen time among urban children with asthma
9. Study Reveals Consumers Want to Buy Products That Dental Hygienists Recommend
10. Methamphetamine use cost the US about $23 billion in 2005, RAND study estimates
11. USC study finds that green tea blocks benefits of cancer drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2017)... ... ... The DuPage County law firm of Mirabella Kincaid Frederick & Mirabella, ... Cusack joins the team ready to provide clients with vigorous representation in a number ... Illinois, with a BA in Social Work. She earned her JD from Western Michigan ...
(Date:7/28/2017)... ... 2017 , ... Gocella Insurance Agency, a Cheektowaga based partnership ... in and around the greater Buffalo metropolitan area, is announcing the firm’s 25th ... The Make-A-Wish Foundation is an internationally recognized nonprofit that works to improve the ...
(Date:7/27/2017)... Denville, NJ (PRWEB) , ... July 27, 2017 ... ... now a Diplomate of the American Board of Oral Implantology/Implant Dentistry (ABOI/ID). After ... one of the nation’s leading providers of dental implants . Dr. Kimowitz ...
(Date:7/27/2017)... Viejo, CA (PRWEB) , ... July 27, 2017 , ... ... Cut Pro X . This Final Cut Pro X exclusive features transitions that contain ... and add rotation to the transition using intuitive drop-down menus. TransPanel Volume 4 makes ...
(Date:7/27/2017)... ... July 27, 2017 , ... ... announces the internal promotion of Elrene Clinkscales to Vice President of Revenue Cycle ... Remittance Management, reporting to Derek Morkel, chief executive officer (CEO). , Elrene has ...
Breaking Medicine News(10 mins):
(Date:7/20/2017)... -- Prime Therapeutics LLC (Prime) released this statement from its Chief ... for Clinical and Economic Review,s (ICER) public meeting ... of abuse-deterrent formulations (ADF) of opioids. Prime was the sole ... "The ICER data ... use of abuse-deterrent formulations (ADF) in opioids in terms of ...
(Date:7/14/2017)... It should come as no surprise to anyone ... the midst of a crippling opioid epidemic. According to the ... of overdose deaths from opiate-based medications has quadrupled, Says, Dr. ... dead from 2001 to 2015". During this time, the prescription ... quadrupled, drawing a compelling link between prescription and eventual addiction. ...
(Date:7/12/2017)... July 12, 2017  Eli Lilly and Company (NYSE: ... generic companies to resolve pending patent litigation in the U.S. ... regarding the Cialis ® (tadalafil) unit dose ... 26, 2020. As part of the agreement, Cialis exclusivity is ... 2018. "The unit dose patent for Cialis is ...
Breaking Medicine Technology: